Albireo
Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Published in Health Business Week, December 4th, 2009
favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study under an IND recently placed into effect by the FDA.
Keywords: Clinical Trial Research,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2009-12-04)
More Articles from Health Business Week
- 1-800-GOT-MOLD?
1-800-GOT-MOLD?'s Dog Detectives Have a Leg Up on the Competition - 3M
3M Introduces Three New Lubricants to Protect Cable During Installation - 4SC AG
4SC Successfully Completes Capital Increase - AARP Idaho
More Idaho Docs Expected To Leave Medicare With 22% Pay Cut Looming - AARP Idaho
Survey Finds AARP Members Back Health Care Reform Legislation - AARP Illinois
Survey Finds Nearly 70 Percent of Illinois AARP Members Back Health Care Reform Legislation - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
